Microviable Therapeutics, a Gijòn, Asturias, Spain-based preclinical stage biotechnology company, raised €1.5M in Seed funding.
The round was led by Inmunomet Intolerancia y Disbiosis SL.
Spun out from the Spanish National Research Council in 2016, and led by CEO Claudio Hidalgo Cantabrana, Microviable Therapeutics focuses on developing novel technologies and therapeutic products from the microbiota. Over the last years, the company launched a product for microbiota sampling that has grown exponentially into an international market with clients across fifteen different countries. Moreover, it has developed technology to store human microbiota for downstream therapeutic applications.
The company intends to use the funds to enhance its therapeutic development platform and advance its pipeline to the clinical stage. The lead product, MVT-201, is under evaluation at pre-clinical stage with positive results. The microbiota-derived product development platform also includes rationally design and defined bacterial consortia that will be advanced with this funding.
FinSMEs
21/04/2022